CBD Acts on Two Newly Discovered Brain Receptors Linked to Alzheimer's and Parkinson's
CBD was found to act as an inverse agonist on GPR3 and GPR6 receptors, which are linked to Alzheimer's and Parkinson's disease, representing entirely new molecular targets for this cannabis compound.
Quick Facts
What This Study Found
This study identified two previously unknown molecular targets for CBD: GPR3 and GPR6, orphan receptors with no confirmed endogenous activators that are phylogenetically related to cannabinoid receptors.
Using a beta-arrestin2 recruitment assay, the researchers tested various endocannabinoids and phytocannabinoids against both receptors. Among all cannabinoids tested, CBD was the standout, significantly reducing beta-arrestin2 recruitment to both GPR3 and GPR6 in a concentration-dependent manner.
This means CBD acts as an inverse agonist at these receptors, reducing their constitutive (baseline) activity. CBD showed higher potency at GPR6 than GPR3.
The significance lies in what these receptors do: GPR3 has been implicated in Alzheimer's disease pathology, while GPR6 plays potential roles in Parkinson's disease. This discovery suggests that some of CBD's reported neuroprotective effects may work through these receptors rather than through the classical CB1 and CB2 cannabinoid receptors.
Key Numbers
CBD significantly reduced beta-arrestin2 recruitment at both receptors in a concentration-dependent manner, with higher potency at GPR6 than GPR3.
How They Did This
In vitro study using beta-arrestin2 recruitment assays to test the activity of multiple endocannabinoids and phytocannabinoids at human GPR3 and GPR6 receptors. Concentration-response curves were generated for CBD at both receptors.
Why This Research Matters
This is the first demonstration that GPR3 and GPR6 are molecular targets for CBD. If CBD's effects on these receptors translate to therapeutic benefit, it could provide a mechanistic basis for using CBD in neurodegenerative diseases, moving beyond anecdotal reports to targeted pharmacology.
The Bigger Picture
CBD has been attributed many potential therapeutic effects, but the molecular mechanisms have been unclear. Identifying GPR3 and GPR6 as targets provides specific, testable hypotheses for how CBD might work in neurodegenerative diseases and moves CBD pharmacology beyond the "it does everything" narrative toward specific receptor-level understanding.
What This Study Doesn't Tell Us
In vitro study only, with no animal model or clinical validation. Inverse agonism at these receptors in a cell assay does not guarantee therapeutic benefit in the brain. The functional consequences of reducing GPR3/GPR6 signaling in living organisms remain to be determined.
Questions This Raises
- ?Would CBD's effects on GPR3 slow amyloid production in Alzheimer's disease models?
- ?Could GPR6 modulation by CBD improve dopamine signaling in Parkinson's models?
- ?Are there other "orphan" receptors that respond to cannabinoids?
Trust & Context
- Key Stat:
- First discovery that CBD acts on GPR3 (Alzheimer's-linked) and GPR6 (Parkinson's-linked) receptors
- Evidence Grade:
- In vitro molecular pharmacology study. Preliminary but represents a novel discovery of CBD targets with therapeutic implications.
- Study Age:
- Published in 2017.
- Original Title:
- GPR3 and GPR6, novel molecular targets for cannabidiol.
- Published In:
- Biochemical and biophysical research communications, 490(1), 17-21 (2017)
- Authors:
- Laun, Alyssa S, Song, Zhao-Hui(2)
- Database ID:
- RTHC-01429
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Could CBD help with Alzheimer's or Parkinson's disease?
This study discovered that CBD acts on two receptors (GPR3 and GPR6) that are linked to these diseases. This provides a molecular basis for potential therapeutic effects, but laboratory receptor activity does not yet prove clinical benefit in patients.
How does CBD work in the brain?
Unlike THC, CBD does not strongly activate CB1 or CB2 receptors. This study found it acts on different receptors entirely (GPR3 and GPR6), suggesting CBD's brain effects may work through mechanisms distinct from the classical endocannabinoid system.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-01429APA
Laun, Alyssa S; Song, Zhao-Hui. (2017). GPR3 and GPR6, novel molecular targets for cannabidiol.. Biochemical and biophysical research communications, 490(1), 17-21. https://doi.org/10.1016/j.bbrc.2017.05.165
MLA
Laun, Alyssa S, et al. "GPR3 and GPR6, novel molecular targets for cannabidiol.." Biochemical and biophysical research communications, 2017. https://doi.org/10.1016/j.bbrc.2017.05.165
RethinkTHC
RethinkTHC Research Database. "GPR3 and GPR6, novel molecular targets for cannabidiol." RTHC-01429. Retrieved from https://rethinkthc.com/research/laun-2017-gpr3-and-gpr6-novel
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.